As astrocytes play a dual role in both preventing and contributing to disease pathogenesis, they represent an important target in AD research, where various mechanisms can be used to modulate their activity for therapeutic benefit 20,125
Here are some alternative medications and supplements to explore: Treatments for Diabetes All GLP-1 RAs are FDA approved for treating diabetes
[3] Semaglutide is administered as a once-weekly subcutaneous injection, with a recommended titration schedule starting at 0.25mg for four weeks, then 0.5mg, with potential increase to 1mg if needed
Am J Hum Genet 36:277282 Servais A, Moriniere V, Grunfeld JP, Noel LH, Goujon JM, Chadefaux-Vekemans B, Antignac C (2008) Late-onset nephropathic cystinosis: clinical presentation, outcome, and genotyping
Vyleesi Label Protocol (FDA-approved) Parameter Dose Value 1.75 mg Source Vyleesi label / Mayo Clinic drug summary Parameter Route Value Subcutaneous (abdomen or thigh) Source Vyleesi label Parameter Timing Value 45 minutes before sexual activity Source Vyleesi label Parameter Maximum frequency Value 1 dose per 24 hours Source Vyleesi label Parameter Maximum monthly use Value 8 doses per month Source Vyleesi label Parameter Approved population Value Premenopausal women with HSDD Source Vyleesi label Reflects the FDA-approved Vyleesi label as summarized by Mayo Clinic (last updated Feb 2026)
Structural (10+ years) : Reconsider whether weight-loss drugs should be treated as luxury goods or as primary prevention tools
